Abstract:The discovery of hybridoma technology, described by Kohler and Milstein in 1975, and the resulting ability to generate monoclonal antibodies (mAbs) initiated a new era in antibody research and clinical development. However, limitations of the hybridoma technology as a routine antibody generation method in conjunction with high immunogenicity responses have led to the development of alternative approaches for the streamlined identification of most effective antibodies. Within this context, display selection technologies such as phage display, ribosome display, yeast display, bacterial display, and mammalian cell surface display have been widely promoted over the past three decades as ideal alternatives to traditional hybridoma methods. The display of antibodies on phages is probably the most widespread and powerful of these methods and, since its invention in late 1980s, significant technological advancements in the design, construction, and selection of antibody libraries have been made, and several fully human antibodies generated by phage display are currently approved or in various clinical development stages. With evolving novel disease targets and the emerging of a new generation of therapeutic antibodies, such as bispecific antibodies, antibody drug conjugates (ADCs), and chimeric antigen receptor T (CAR - T) cell therapies, it is clear that phage display is expected to continue to play a central role in antibody development. Nevertheless, for non-standard and more demanding cases aiming to generate best-in-class therapeutic antibodies against challenging targets and unmet medical needs, in vivo phage display selections by which phage libraries are directly injected into animals or humans for isolating and identifying the phages bound to specific tissues offer an advantage over conventional in vitro phage display screening procedures. Thus, in the present review, we will first summarize a general overview of the antibody therapeutic market, the different types of antibody fragments, and novel engineered variants that have already been explored. Then, we will discuss the state-of-the-art of in vivo phage display methodologies as a promising emerging selection strategy for improvement antibody targeting and drug delivery properties.

Phage display for discovery of anticancer antibodies

Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Phage display screening of therapeutic peptide for cancer targeting and therapy

Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy

Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

The role of phage display in therapeutic antibody discovery

Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy

Evolution of phage display libraries for therapeutic antibody discovery

Phage Display Libraries for Antibody Therapeutic Discovery and Development

Preparation of Phage Display cDNA Libraries for Identifying Immunogenic Tumor Antigens: Challenges in Functional cDNA Presentation and Approaches to Overcoming Them

Phage display technology and its impact in the discovery of novel protein-based drugs

In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties

Phage-based peptides for pancreatic cancer diagnosis and treatment: alternative approach

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

[Phage antibody library technology in tumor therapy: a review].

Advancement in the development of single chain antibodies using phage display technology

Progress in Phage-displayed Antibody Libraries

Phage display enables machine learning discovery of cancer antigen specific TCRs

Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy